BridgeBio Pharma Change in Accounts Receivable 2018-2024 | BBIO
BridgeBio Pharma annual/quarterly change in accounts receivable history and growth rate from 2018 to 2024. Change in accounts receivable can be defined as the increase or decrease in accounts receivable for the given period.
- BridgeBio Pharma change in accounts receivable for the quarter ending December 31, 2024 was $0M, a 0% increase year-over-year.
- BridgeBio Pharma change in accounts receivable for the twelve months ending December 31, 2024 was $0M, a 0% increase year-over-year.
- BridgeBio Pharma annual change in accounts receivable for 2024 was $0B, a 0% decline from 2023.
- BridgeBio Pharma annual change in accounts receivable for 2023 was $0B, a 0% decline from 2022.
- BridgeBio Pharma annual change in accounts receivable for 2022 was $0B, a 0% decline from 2021.
BridgeBio Pharma Annual Change in Accounts Receivable
(Millions of US $) |
| 2024 |
$N/A |
| 2023 |
$N/A |
| 2022 |
$N/A |
| 2021 |
$N/A |
| 2020 |
$N/A |
| 2019 |
$N/A |
| 2018 |
$N/A |
| 2017 |
$N/A |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$6.894B |
$0.222B |
|
BridgeBio Pharma Inc. discovers, develops and innovates drugs for genetic diseases. The Company's product platform consists of Mendelian, Oncology and Gene therapy. Its product pipeline includes BBP-265, BBP-831, BBP-631 and BBP-454 which are in clinical stage. BridgeBio Pharma Inc. is based in CA, United States.
|
